Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on
developing novel medicines for COVID-19 and other viral
ARDS-related diseases and for oncology, today announced financial
results for its fiscal 2022 fourth quarter and full year ended
September 30, 2022 and provided a business update.
“This has been a transformational year for Veru. We
reported positive Phase 3 results demonstrating that sabizabulin
treatment resulted in a statistically and clinically significant
reduction in death in hospitalized moderate to severe COVID-19
patients at high risk for ARDS and death, which was published in
the NEJM Evidence®,” said Mitchell Steiner, M.D., Chairman,
President, and Chief Executive Officer of Veru. “As sabizabulin is
being reviewed in the U.S. and internationally for potential
emergency use authorization, we are preparing for commercialization
and will be ready to deliver this treatment to patients, if
authorized.”
Dr. Steiner added, “While FC2 revenue decreased this past year
due to business challenges experienced by our largest telemedicine
customers, we are working diligently to regenerate FC2 product
sales, and our recently launched telemedicine platform has shown
steady market uptake to date.”
Infectious Disease Program
HighlightsSabizabulin: A Novel Oral,
First-in-Class, Microtubule Disruptor for the Treatment of
Hospitalized Moderate to Severe COVID-19 Patients at High Risk for
Acute Respiratory Distress Syndrome (ARDS)In November
2022, the U.S. FDA’s Pulmonary-Allergy Drugs Advisory Committee met
with the Company to review its request for Emergency Use
Authorization (EUA) of sabizabulin. The Advisory Committee voted
8-5 that the known and potential benefits of sabizabulin when used
for the treatment of adult patients hospitalized with COVID-19 at
high risk of ARDS do not outweigh the known and potential risks of
sabizabulin. The FDA considers the Advisory Committee’s input as
part of their review, but the FDA makes the final decision on
issuing an EUA.
In October 2022, the Company presented data from the Phase 3
trial of sabizabulin in a late-breaker oral presentation at IDWeek
(Infectious Disease Week) 2022.
In August 2022, Australia’s Therapeutic Goods Administration
(TGA) granted the Company an expedited provisional registration
regulatory pathway for sabizabulin treatment in hospitalized
COVID-19 patients at high risk for ARDS.
In August 2022, the Company presented the Phase 3 trial results
of sabizabulin at the 11th International Conference on Emerging
Infectious Diseases (ICEID).
In July 2022, European Medicines Agency’s (EMA) Emergency Task
Force (ETF) initiated the review of sabizabulin for emergency use
in the EU member states.
In July 2022, United Kingdom’s (UK’s) Medicines and Healthcare
Products Regulatory Agency (MHRA) supported an expedited review of
the marketing authorization application for sabizabulin treatment
in hospitalized COVID-19 patients at high risk for ARDS.
On July 6, 2022, The New England Journal of Medicine Evidence®
published results from the Phase 3 trial evaluating the efficacy
and safety of oral sabizabulin in hospitalized COVID-19
patients.
Breast Cancer Program Highlights
Enobosarm, a Novel Oral Selective Androgen Receptor
Targeting Agonist, for the 3rd Line Treatment
of AR+ER+HER2- Metastatic Breast Cancer with sufficient AR
Expression
We are enrolling patients in the Phase 3 multicenter,
international, open label, randomized (1:1) ARTEST registrational
trial to evaluate enobosarm versus either exemestane ± everolimus
or a selective estrogen receptor modulator (SERM) as the active
comparator for the treatment of AR+ER+HER2- metastatic breast
cancer in approximately 210 patients with sufficient AR expression
in their breast cancer tissue who had previously received a
nonsteroidal aromatase inhibitor, fulvestrant, and a CDK4/6
inhibitor. In January 2022, the FDA granted Fast Track designation
to the ARTEST Phase 3 registrational program.
Enobosarm and Abemaciclib, CDK 4/6 Inhibitor,
Combination Therapy for the 2nd Line
Treatment of AR+ER+HER2- Metastatic Breast Cancer with
sufficient AR Expression
We are enrolling patients in the Phase 3 multicenter, open
label, randomized (1:1), active control ENABLAR-2 trial to evaluate
enobosarm and abemaciclib combination versus an alternative
estrogen blocking agent (fulvestrant or an aromatase inhibitor) in
subjects with AR+ER+HER2- metastatic breast cancer who have failed
first line palbociclib (a CDK 4/6 inhibitor) plus an estrogen
blocking agent (non-steroidal aromatase inhibitor or fulvestrant)
and who have sufficient AR expression in their breast cancer tissue
in approximately 186 subjects. We have a collaboration and supply
agreement with Eli Lilly for this trial.
Sabizabulin for the 3rd Line
Treatment of AR+ER+HER2- Metastatic Breast Cancer with
sufficient AR Expression
We intend to conduct a Phase 2b open label, multicenter,
randomized (1:1) trial evaluating sabizabulin 32mg versus active
comparator (exemestane ± everolimus or a SERM, physician’s
choice) for the treatment of AR+ER+HER2- metastatic breast cancer
in approximately 200 patients with sufficient AR expression in
their breast cancer tissue who have previously received a
nonsteroidal aromatase inhibitor, fulvestrant, and a CDK4/6
inhibitor.
Prostate Cancer Program Highlights
Sabizabulin for the Treatment of Metastatic Castration and
Androgen Receptor Targeting Agent Resistant Prostate
Cancer
We are enrolling patients in the Phase 3 VERACITY open label,
randomized (2:1), multicenter trial evaluating sabizabulin 32mg
versus an alternative androgen receptor targeting agent for the
treatment of chemotherapy naïve men with metastatic castration
resistant prostate cancer who have tumor progression after
previously receiving at least one androgen receptor targeting
agent. The primary endpoint is radiographic progression free
survival in approximately 245 patients.
VERU-100, a Novel Proprietary Long-Acting
Gonadotropin-Releasing Hormone (GnRH) Antagonist Peptide 3-Month
Subcutaneous Depot Formulation, for Androgen Deprivation
Therapy of Advanced Prostate Cancer
We are enrolling patients in the Phase 2 clinical dose finding
trial of VERU-100 for androgen deprivation therapy of advanced
prostate cancer. The trial design for a future Phase 3
registrational trial of approximately 100 patients has been agreed
upon by the FDA.
Urev - Sexual Health Program Highlights
ENTADFI™ (tadalafil and finasteride) capsule, a new
Treatment for Benign Prostatic Hyperplasia (BPH)
The Company recently initiated the U.S. commercial launch and
availability of ENTADFI™– an FDA-approved oral, once daily product
for benign prostatic hyperplasia (BPH) that is approved for men
with an enlarged prostate that are experiencing the signs and
symptoms of BPH for up to 26 weeks.
FC2 Female Condom/Internal
Condom®
The Company markets and sells the FC2 Female Condom®, an
FDA-approved product for dual protection against unplanned
pregnancy and the transmission of sexually transmitted
infections.
Full Year Financial Summary: Fiscal 2022 vs Fiscal
2021
- Total net revenues decreased to $39.4 million from $61.3
million
- Gross profit decreased to $30.6 million from $47.9 million
- Gross margin remained consistent at 78% of net revenues
- Research and development expenses increased to $70.6 million
from $32.7 million
- Operating loss was $83.2 million compared with operating income
of $13.0 million, which included an $18.4 million gain on the
December 2020 sale of the PREBOOST® business
- Net loss was $83.8 million, or $1.05 per diluted share,
compared with net income, which included the gain on sale of the
PREBOOST business, of $7.4 million, or $0.09 per diluted share
Balance Sheet Information
- Cash and cash equivalents were $80.2 million as of September
30, 2022 versus $122.4 million as of September 30, 2021
- Net accounts receivable were $3.6 million as of September 30,
2022 versus $8.8 million as of September 30, 2021
Event DetailsThe audio webcast will be
accessible under “Investor Kit” in the Investors page of the
Company’s website at www.verupharma.com. To join the conference
call via telephone, please dial 1-800-341-1602 (domestic) or
1-412-902-6706 (international) and ask to join the Veru Inc. call.
An archived version of the audio webcast will be available for
replay on the Company’s website for approximately three months. A
telephonic replay will be available on December 5, 2022 at
approximately 12:00 p.m. ET by dialing 1-877-344-7529 (domestic) or
1-412-317-0088 passcode 4646397 (international) for one week.
About Veru Inc.Veru is a biopharmaceutical
company focused on developing novel medicines for COVID-19 and
other viral ARDS-related diseases and for oncology.
Infectious disease program:
The Company has completed a positive Phase 3 COVID-19
study evaluating sabizabulin, an oral, first-in-class, new chemical
entity, microtubule disruptor that has dual anti-inflammatory and
antiviral properties, in hospitalized moderate to severe COVID-19
patients at high risk for ARDS.
A double-blind, randomized, placebo-controlled Phase 3 COVID-19
clinical trial was conducted in 204 hospitalized moderate to severe
COVID-19 patients at high risk for ARDS and death. The primary
endpoint was the proportion of deaths by Day 60. Based on a planned
interim analysis of the first 150 patients randomized, the
Independent Data Monitoring Committee unanimously halted the study
for clear clinical efficacy and no safety concerns were identified.
Treatment with sabizabulin 9 mg once daily resulted in a clinically
meaningful and statistically significant 55.2% relative reduction
in deaths compared to placebo.
Oncology program:
The Company’s late-stage breast cancer development portfolio
comprises enobosarm, a selective androgen receptor targeting
agonist, and sabizabulin.
Current studies on the two drugs include:
- Enrolling Phase 3 ARTEST study of enobosarm in androgen
receptor positive, estrogen receptor positive, and human epidermal
growth factor receptor two negative (AR+ ER+ HER2-) metastatic
breast cancer with sufficient AR expression (third-line metastatic
setting), and which has been granted Fast Track designation by the
FDA.
- Enrolling Phase 3 ENABLAR-2 study of enobosarm + abemaciclib (a
CDK 4/6 inhibitor) combination in AR+ ER+ HER2- metastatic breast
cancer with sufficient AR expression (second-line metastatic
setting). The Company and Eli Lilly and Company have entered into a
clinical study collaboration and supply agreement for the ENABLAR-2
study. Lilly is supplying Verzenio® (abemaciclib).
- Planned Phase 2b study of sabizabulin in AR+ ER+ HER2-
metastatic breast cancer with sufficient AR expression (third-line
metastatic setting).
Veru’s late-stage prostate cancer portfolio comprises
sabizabulin, VERU-100, a long-acting GnRH antagonist, and
zuclomiphene citrate, an oral nonsteroidal estrogen receptor
agonist.
Current studies on these drugs include:
- Enrolling Phase 3 VERACITY study in metastatic castration and
androgen receptor targeting agent resistant prostate cancer prior
to IV chemotherapy.
- Enrolling Phase 2 dose-finding study of VERU-100 in advanced
hormone sensitive prostate cancer.
- Planned Phase 2b study of zuclomiphene citrate to treat hot
flashes in men with advanced prostate cancer undergoing androgen
deprivation therapy.
Commercial sexual health program, Urev, has 2 FDA
approved products:
- ENTADFI™ (tadalafil and finasteride) capsules for oral use, a
new treatment for benign prostatic hyperplasia.
- FC2 Female Condom® (internal condom), for the dual protection
against unplanned pregnancy and the transmission of sexually
transmitted infections which is sold in the U.S. and globally.
Forward-Looking StatementsThe statements in
this release that are not historical facts are “forward-looking
statements” as that term is defined in the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this
release include statements regarding: whether and when the Company
will receive an emergency use authorization or any approval from
FDA or from any regulatory authority outside the U.S. for
sabizabulin for certain COVID-19 patients; whether and when
sabizabulin will become an available treatment option for certain
COVID-19 patients in the U.S. or anywhere outside the U.S.; whether
any additional efficacy or safety clinical studies of sabizabulin
for certain COVID-19 patients will be required by the FDA or any
other regulatory authority as a condition to any authorization or
as a post-authorization requirement; whether the Company will have
sufficient supply of sabizabulin to meet demand, if an emergency
use authorization or other approval is granted in the U.S. or in
any other country; whether the Company will secure any advance
purchase agreement with the U.S. government or any foreign
government; whether the current and future clinical development and
results will demonstrate sufficient efficacy and safety and
potential benefits to secure FDA approval of the Company’s drug
candidates and companion diagnostic; whether the drug candidates
will be approved for the targeted line of therapy; the anticipated
design and scope of clinical studies and FDA acceptance of such
design and scope; whether any regulatory pathways, including the
accelerated Fast Track designations, to seek FDA approval for
sabizabulin, enobosarm or any of the Company’s drug candidates are
or continue to be available; whether the expected commencement and
timing of the Company’s clinical studies, including the Phase 3
ENABLAR-2 study, the sabizabulin monotherapy Phase 2b clinical
study for 3rd line treatment of metastatic breast cancer, the Phase
2 registration clinical study for VERU-100, and the development of
the companion diagnostic will be met; when clinical results from
the ongoing clinical studies will be available, whether
sabizabulin, enobosarm, VERU-100, or zuclomiphene will serve any
unmet need or, what dosage, if any, might be approved for use in
the U.S. or elsewhere, and also statements about the potential,
timing and efficacy of the rest of the Company’s development
pipeline, and the timing of the Company’s submissions to FDA and
FDA’s review of all such submissions; whether any of the selective
clinical properties previously observed in clinical studies of
sabizabulin, enobosarm, VERU-100 or other drug candidates will be
replicated in the current and planned clinical development program
for such drug candidates and whether any such properties will be
recognized by the FDA in any potential approvals and labeling;
whether the companion diagnostic for enobosarm will be developed
successfully or be approved by the FDA for use; whether ENTADFI
will be commercialized successfully, the Company will grow sales of
ENTADFI or the Company will be able to successful partner with any
other entity to grow sales of ENTADFI; whether the telemedicine
customers for FC2 will return to historical ordering patterns or
increase their purchases of FC2 at all; and whether the Company’s
current cash will be sufficient to fund its planned or expected
operations, especially if any authorizations for sabizabulin for
certain COVID-19 patients are not obtained. These forward-looking
statements are based on the Company’s current expectations and
subject to risks and uncertainties that may cause actual results to
differ materially, including unanticipated developments in and
risks related to: the development of the Company’s product
portfolio and the results of clinical studies possibly being
unsuccessful or insufficient to meet applicable regulatory
standards or warrant continued development; the ability to enroll
sufficient numbers of subjects in clinical studies and the ability
to enroll subjects in accordance with planned schedules; the
ability to fund planned clinical development; the timing of any
submission to the FDA or any other regulatory authority and any
determinations made by the FDA or any other regulatory authority;
the possibility that as vaccines become widely distributed the need
for new COVID-19 treatment candidates may be reduced or eliminated;
government entities possibly taking actions that directly or
indirectly have the effect of limiting opportunities for
sabizabulin as a COVID-19 treatment, including favoring other
treatment alternatives or imposing price controls on COVID-19
treatments; the Company’s existing products, including FC2 and
ENTADFI and, if authorized, sabizabulin, and any future products,
if approved, possibly not being commercially successful; the
effects of the COVID-19 pandemic and measures to address the
pandemic on the Company’s clinical studies, supply chain and other
third-party providers, commercial efforts, and business development
operations; the ability of the Company to obtain sufficient
financing on acceptable terms when needed to fund development and
operations; demand for, market acceptance of, and competition
against any of the Company’s products or product candidates; new or
existing competitors with greater resources and capabilities and
new competitive product approvals and/or introductions; changes in
regulatory practices or policies or government-driven healthcare
reform efforts, including pricing pressures and insurance coverage
and reimbursement changes; the Company’s ability to successfully
commercialize any of its products, if approved; risks relating to
the Company's development of its own dedicated direct to patient
telemedicine and telepharmacy services platform, including the
Company's lack of experience in developing such a platform,
potential regulatory complexity, and development costs; the
Company’s ability to protect and enforce its intellectual property;
the potential that delays in orders or shipments under government
tenders or the Company’s U.S. prescription business could cause
significant quarter-to-quarter variations in the Company’s
operating results and adversely affect its net revenues and gross
profit; the Company’s reliance on its international partners and on
the level of spending by country governments, global donors and
other public health organizations in the global public sector; the
concentration of accounts receivable with our largest customers and
the collection of those receivables; the Company’s production
capacity, efficiency and supply constraints and interruptions,
including potential disruption of production at the Company’s and
third party manufacturing facilities and/or of the Company’s
ability to timely supply product due to labor unrest or strikes,
labor shortages, raw material shortages, physical damage to the
Company’s and third party facilities, COVID-19 (including the
impact of COVID-19 on suppliers of key raw materials), product
testing, transportation delays or regulatory actions; costs and
other effects of litigation, including product liability claims;
the Company’s ability to identify, successfully negotiate and
complete suitable acquisitions or other strategic initiatives; the
Company’s ability to successfully integrate acquired businesses,
technologies or products; and other risks detailed from time to
time in the Company’s press releases, shareholder communications
and Securities and Exchange Commission filings, including the
Company’s Form 10-K for the fiscal year ended September 30, 2021
and subsequent quarterly reports on Form 10-Q. These documents are
available on the “SEC Filings” section of our website at
www.verupharma.com/investors. The Company disclaims any intent or
obligation to update these forward-looking statements.
Verzenio® is a registered trademark of Eli Lilly and Company
NEJM Evidence® is a registered trademark of the Massachusetts
Medical Society
Investor Contact:
Samuel FischExecutive Director, Investor
Relations and Corporate CommunicationsEmail:
veruinvestor@verupharma.com
Media Contact:Hannah GendelManager, Corporate
CommunicationsEmail: media@verupharma.com
FINANCIAL SCHEDULES FOLLOW
Veru Inc.Condensed
Consolidated Balance
Sheets(unaudited)
|
|
|
|
|
|
|
September 30, |
|
September 30, |
|
2022 |
|
2021 |
|
|
|
|
|
|
Cash and cash equivalents |
$ |
80,190,675 |
|
$ |
122,359,535 |
Accounts receivable, net |
|
3,550,895 |
|
|
8,794,224 |
Inventories, net |
|
8,618,944 |
|
|
5,574,253 |
Prepaid expenses and other current assets |
|
12,408,960 |
|
|
15,025,475 |
Total current assets |
|
104,769,474 |
|
|
151,753,487 |
|
|
|
|
|
|
Plant and equipment, net |
|
1,185,766 |
|
|
592,603 |
Operating lease right-of-use assets |
|
4,786,915 |
|
|
969,839 |
Deferred income taxes |
|
12,965,985 |
|
|
13,024,550 |
Intangible assets, net |
|
3,977,381 |
|
|
4,048,810 |
Goodwill |
|
6,878,932 |
|
|
6,878,932 |
Other assets |
|
1,561,564 |
|
|
878,502 |
Total assets |
$ |
136,126,017 |
|
$ |
178,146,723 |
|
|
|
|
|
|
Accounts payable |
$ |
22,003,394 |
|
$ |
3,409,771 |
Accrued research and development costs |
|
9,071,503 |
|
|
2,020,445 |
Accrued expenses and other current liabilities |
|
9,193,637 |
|
|
7,099,883 |
Residual royalty agreement liability, short-term portion |
|
1,169,095 |
|
|
3,237,211 |
Total current liabilities |
|
41,437,629 |
|
|
15,767,310 |
|
|
|
|
|
|
Residual royalty agreement liability, long-term portion |
|
9,656,441 |
|
|
9,397,136 |
Operating lease liability, long-term portion |
|
4,093,667 |
|
|
609,921 |
Other liabilities |
|
99,644 |
|
|
78,412 |
Total liabilities |
|
55,287,381 |
|
|
25,852,779 |
|
|
|
|
|
|
Total stockholders'
equity |
|
80,838,636 |
|
|
152,293,944 |
Total liabilities and
stockholders' equity |
$ |
136,126,017 |
|
$ |
178,146,723 |
|
|
|
|
|
|
Veru Inc.Condensed
Consolidated Statements of
Operations(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months EndedSeptember
30, |
|
Year EndedSeptember 30, |
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenues |
$ |
2,588,631 |
|
|
$ |
15,646,460 |
|
|
$ |
39,354,352 |
|
|
$ |
61,259,528 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
2,083,226 |
|
|
|
3,337,282 |
|
|
|
8,762,964 |
|
|
|
13,332,305 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
505,405 |
|
|
|
12,309,178 |
|
|
|
30,591,388 |
|
|
|
47,927,223 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
26,890,426 |
|
|
|
8,255,592 |
|
|
|
70,646,103 |
|
|
|
32,694,405 |
|
Selling, general and administrative |
|
18,287,515 |
|
|
|
5,924,812 |
|
|
|
43,168,845 |
|
|
|
20,670,319 |
|
Total operating expenses |
|
45,177,941 |
|
|
|
14,180,404 |
|
|
|
113,814,948 |
|
|
|
53,364,724 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on sale of PREBOOST® |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
18,410,158 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income |
|
(44,672,536 |
) |
|
|
(1,871,226 |
) |
|
|
(83,223,560 |
) |
|
|
12,972,657 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-operating income
(expenses) |
|
3,661,517 |
|
|
|
(2,779,321 |
) |
|
|
(316,063 |
) |
|
|
(8,707,421 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income before income
taxes |
|
(41,011,019 |
) |
|
|
(4,650,547 |
) |
|
|
(83,539,623 |
) |
|
|
4,265,236 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
(benefit) |
|
11,589 |
|
|
|
(356,067 |
) |
|
|
236,397 |
|
|
|
(3,129,138 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income |
$ |
(41,022,608 |
) |
|
$ |
(4,294,480 |
) |
|
$ |
(83,776,020 |
) |
|
$ |
7,394,374 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income per basic
common share outstanding |
$ |
(0.51 |
) |
|
$ |
(0.05 |
) |
|
$ |
(1.05 |
) |
|
$ |
0.10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic weighted average common
shares outstanding |
|
80,324,106 |
|
|
|
79,887,081 |
|
|
|
80,122,526 |
|
|
|
76,272,853 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income per diluted
common share outstanding |
$ |
(0.51 |
) |
|
$ |
(0.05 |
) |
|
$ |
(1.05 |
) |
|
$ |
0.09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted weighted average
common shares outstanding |
|
80,324,106 |
|
|
|
79,887,081 |
|
|
|
80,122,526 |
|
|
|
83,802,420 |
|
Veru Inc.Condensed
Consolidated Statements of Cash
Flows(unaudited)
|
|
|
|
|
|
|
Year EndedSeptember 30, |
|
2022 |
|
|
2021 |
|
|
|
|
|
|
|
Net (loss) income |
$ |
(83,776,020 |
) |
|
$ |
7,394,374 |
|
|
|
|
|
|
|
Adjustments to reconcile net
(loss) income to net cash used in operating activities |
|
10,389,053 |
|
|
|
(15,682,840 |
) |
|
|
|
|
|
|
Changes in operating assets
and liabilities |
|
25,881,963 |
|
|
|
(7,282,558 |
) |
|
|
|
|
|
|
Net cash used in operating
activities |
|
(47,505,004 |
) |
|
|
(15,571,024 |
) |
|
|
|
|
|
|
Net cash provided by investing
activities |
|
4,266,948 |
|
|
|
14,623,351 |
|
|
|
|
|
|
|
Net cash provided by financing
activities |
|
1,069,196 |
|
|
|
109,718,430 |
|
|
|
|
|
|
|
Net (decrease) increase in
cash |
|
(42,168,860 |
) |
|
|
108,770,757 |
|
|
|
|
|
|
|
Cash at beginning of
period |
|
122,359,535 |
|
|
|
13,588,778 |
|
|
|
|
|
|
|
Cash at end of period |
$ |
80,190,675 |
|
|
$ |
122,359,535 |
|
|
|
|
|
|
|
Veru (NASDAQ:VERU)
Historical Stock Chart
From Feb 2024 to Mar 2024
Veru (NASDAQ:VERU)
Historical Stock Chart
From Mar 2023 to Mar 2024